Skip to main content

Table 2 Representative preclinical experiments about immunosuppressive cells

From: Next frontier in tumor immunotherapy: macrophage-mediated immune evasion

Cell Target Drug name Animal model Combination therapy Effect on the TME References
MDSC NAMPT FK866 and MV87 Fibrosarcoma mouse model PD-1 antibody Decrease MDSCs, increase T cell [91]
Resveratrol Lewis lung carcinoma bearing mice - Decrease MDSCs, increase T cell [95]
γ-secretase DAPT Head and neck squamous cell carcinoma - Decrease MDSCs/TAM/Tregs [118]
DCs CD-11b ADH-503 Pancreatic ductal adenocarcinoma PD-1/41BB antibody Promote M1 polarization; Increase cDCs/T cell [103]
TLR-7 /IL-10 let7b Breast cancer - Activate TIDCs; Increase secretion of IL-12/IL-10 [114]
CD169 CD169 antibodies Melanoma - Increase CD8+T cell response -
TANs SIRPα KWAR23 Burkitt’s lymphoma mice model Anti-CD70 antibody Enhance neutrophils and macrophages antitumor activity [109]
B11 EFNB2-EphB4 Pancreatic ductal adenocarcinoma Radiation Decrease Tregs, macrophages, and neutrophils [113]
Tregs IL-23 Guselkumab Renal cell carcinoma - Decrease Tregs; Decrease secretion of IL-10/TGF-β; Increase cytotoxicity of CD8+T cells [135]
TLR1/2 Pam3CSK4 B16/F10 melanoma model CTLA-4 antibody Increase M1/T cells; Decrease Tregs [142]
CAFs Bromodoma JQ1/ricolinostat Non-small cell lung cancer model - Increase T cell, decrease M2 -
HSP90 Octyl gallate Pancreatic ductal adenocarcinoma - Decrease M2 [146]
mPGES-1 CIII Neuroblastoma tumor - Decrease M2 [151]